tbuckley/cabot-search huggingface dataset:
Equivalent Racial Outcome After Conformal Radiotherapy for Prostate Cancer: A Single Departmental Experience
Authors: Philip P. Connell, Lani Ignacio, Daniel Haraf, Azhar M. Awan, Howard Halpern, Ibrahim Abdalla, Jaishanker Nautiyal, Ashesh B. Jani, Ralph R. Weichselbaum, Srinivasan Vijayakumar
Journal: Journal of Clinical Oncology (2001)

PURPOSE: African-American (AA) men with prostate cancer present with advanced disease, relative to white (W) men. This report summarizes our clinical and biochemical control (bNED) rates after conformal radiotherapy (RT). In particular, we aim to characterize any race-based outcome differences seen after comparable treatment. PATIENTS AND METHODS: We reviewed 893 patients (418 AA and 475 W) with clinically localized prostate cancer treated between 1988 and 1997. Neoadjuvant hormonal blockade was used in 22.5% of cases, and all patients received conformal RT to a median dose of 68 Gy (range, 60 to 74.8 Gy). Biochemical failure was defined according to the American Society of Therapeutic Radiology and Oncology consensus definition. Median follow-up was 24 months (range, 1 to 114 months). RESULTS: The 5-year actuarial survival, disease-free survival, and bNED rates for the entire population were 80.5%, 70.0%, and 57.6%, respectively. When classified by prognostic risk category, the 5-year actuarial bNED rates were 78.7% for favorable, 57.7% for intermediate, and 39.8% for unfavorable category patients. AA men presented at younger ages and with more advanced disease. Controlled for prognostic risk category, AA and W men had similar 5-year actuarial bNED rates in favorable (78% v 79%, P = .91), intermediate (52% v 62%, P = .44), and unfavorable categories (36% v 45%, P = .09). Race was not an independent prognostic factor (P = .36). CONCLUSION: Conformal RT is equally effective for AA and W patients. More research is needed in order to understand and correct the advanced presentations in AA men. These data suggest a need for early screening in AA populations.
Abstract P181: Factors Associated with Implantable Cardioverter-Defibrillator Implantation
Authors: Cynthia Ennis, Matthew McGuiness, Rishi Vohora, Stephanie Ennis, Lawrence Rosenthal
Journal: Circulation (2008)

Introduction: While implantable cardioverter-defibrillators (ICDs) have been shown to reduce mortality in high risk populations (EF≤ 35%), the percentage of eligible candidates receiving ICDs has n...
Occupational asthma to argan powder: First evidence
Authors: Emmanuelle Penven, Fabrice Herin, Mathias Poussel, Sandrine Jacquenet, Cécile Poussel, Cécile Guidat, Isabelle Thaon, Annick Barbaud, Christophe Paris
Journal: European Respiratory Journal (2013)

Nine patients from a cosmetic factory were examined in our occupational diseases department, following the appearance of respiratory symptoms in relation with argan cakes handling.  Methods. Operators were exposed to the three forms of the product (crude granulates, powder or liquid) depending on the step of the process.  All patients systematically underwent a standardized questionnaire on occupational and medical history. Then, medical investigations were realized, comprising, in particularly, peakflow recording, metacholine challenge test, research of specific IgE to argan by immunoblotting technique, prick-tests (PT) to argan powder and some other vegetal allergens. When necessary, a specific challenge test was organized with argan powder. Finally, a research of analogy of peptides sequences were researched, after tandem mass spectrometry (Orbitrap XL) analyses, in vegetal databases.  Results. About the 9 workers, 4 have rhinitis and/or asthma symptoms when handling argan powder. Three subjects presented positive PT to current respiratory allergens, hazelnuts and, for 2 of them, a positive prick-test to argan. Those with a suspected asthma also have a positive specific challenge test to argan.  Sequencing analyses demonstrated analogy for 3 groups of vegetal proteins, known to be responsible of allergies.  Conclusion. We reported first evidence of occupational asthma in 3 patients to argan powder, proved by specific challenge test. First results of allergens structure analyses suggested the role of a vegetal protein-like.
Immunotherapy in Friend Virus Leukemia. I. Prevention of Friend Leukemia in the Offspring of Immunized Mothers&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Britta Wahren
Journal: JNCI Journal of the National Cancer Institute (1968)

Inhibition of a primary virus-induced leukemia was demonstrafed in a model system. DBA/2 Friend leukemic cells, which contain a new virus-directed cellular antigen, were used to immunize DBA/2 or DBA/2 hybrid females. The offspring were effectively protected against large doses of Friend virus for at least 3 weeks after birth. The kinetics of the virus-host interaction and the duration of immunity were studied. After 4–6 weeks the acquired resistance began to decrease. In 10-week-old offspring from immunized mothers the resistance was completely lost, but reappeared after another few weeks. Since living Friend leukemia cells were used for immunization of the mother, the late resistance of the offspring may be explained by a transmission of a small amount of virus, to which an active immunity was formed. Accordingly, only the early resistance was seen if the mothers were immunized with formalin-inactivated Friend virus. Newborn, immunologically incompetent mice were thus shown to be passively protected by maternal antibodies for the time needed to develop an active immune response to Friend virus leukemia. Foster-nursing experiments showed that immunity was transferred mainly by milk and was effective on the first day of suckling. Leukemic mothers did not transfer any immunity. Evaluation of the influence of sex and age showed that young females were more susceptible to Friend virus infection than males of the same strain, and that a natural resistance appeared after the first 3 weeks.
Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from endobronchial ultrasound-guided transbronchial needle aspiration specimen
Authors: Jinwoo Lee, Young Sik Park, Chang-Hoon Lee, Sang-Min Lee, Jae-Joon Yim, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han
Journal: European Respiratory Journal (2013)

Background: Despite global efforts to control tuberculosis (TB), diagnosis of extrapulmonary TB, especially intrathoracic TB lymphadenitis, remains a challenge. Histology is time-consuming and tissue microscopy after special staining is often negative. Xpert MTB/RIF assay is considered useful for rapid molecular diagnosis of pulmonary TB. However, its use for diagnosing TB lymphadenitis has not yet been widely validated.  Objectives: To assess the role of Xpert MTB/RIF in diagnosing intrathoracic TB lymphadenitis from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) specimen.  Methods: Twenty-eight patients with enlarged hilar and/or mediastinal lymph nodes who underwent EBUS-TBNA and Xpert MTB/RIF assay using EBUS-TBNA specimens were retrospectively reviewed. Both acid-fast bacilli smear and culture of EBUS-TBNA specimens were performed in all patients.  Results: The median age of the patients was 66 years and 54% of the patients were male. Biopsies obtained by EBUS-TBNA showed malignant cells in 9 patients. Among 19 patients in which EBUS-TBNA had not detected malignancy, 3 patients had positive Xpert MTB/RIF tests. Histology for all three patients were sufficient to exclude malignancy but insufficient to confirm TB infection. Tissue smears were negative for all 3 patients and culture was positive for 1 patient. All three patients are being treated with anti-TB medications.  Conclusion: In patients with enlarged hilar and/or mediastinal lymph nodes with low suspicion of malignancy, combination of Xpert MTB/RIF assay with histology could lead to early diagnosis and treatment of intrathoracic TB lymphadenitis.
Photodynamic Therapy for Non-Melanoma Skin Cancer
Authors: Sari M. Fien, Allan R. Oseroff
Journal: Journal of the National Comprehensive Cancer Network (2007)

Photodynamic therapy (PDT) involves the administration of a photosensitizing drug and its subsequent activation by light at wavelengths matching the absorption spectrum of the photosensitizer. Because the skin is readily accessible to light-based therapies, PDT with systemic and particularly with topical agents has become important in treating cutaneous disorders. Topical PDT is indicated for treating actinic keratosis, superficial or thin non-melanoma skin cancer, including some cases of nodular basal cell carcinoma, and some cutaneous lymphomas. Advantages of aminolevulinic acid/methyl aminolevulinate PDT include the possibility of simultaneous treatment of multiple tumors and large surface areas, good cosmesis, and minimal morbidity, such as bleeding, scarring, or infection.
Use of Artificial Sweeteners by Cancer Patients&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Alan S. Morrison
Journal: JNCI Journal of the National Cancer Institute (1979)

Current daily use of artificial sweeteners (AS) and diet drinks was evaluated for 1,862 patients hospitalized for cancer and for 10,874 "control" patients hospitalized for other conditions believed not to be associated with use of these substances. The data were derived from an ongoing survey in seven countries. For cancer of most sites, the age-standardized proportion of users of AS was somewhat less than that for controls. A greater proportion of users among cancer patients than among controls was noted only for cancer of the stomach among women. Little information on urinary tract cancer was available; there were no users of AS among 13 patients with cancer of the bladder, 5 with cancer of the renal pelvis, and 2 with cancer of the ureter. There were 455 cancer patients known to have been interviewed during their initial hospitalization for the disease. Based on these cases, an age-sex-country-standardized estimate of cancer incidence for users of AS, relative to nonusers, was 1.0. Only a very small proportion of patients reported daily use of diet drinks, and the proportion of users did not differ substantially between cancer patients and controls. The present data provide virtually no support for an overall positive association of AS with cancer.
Rectal cancer surgery: is restoration of intestinal continuity the primary aim?
Authors: C R Selvasekar, G David, D J Corless, A U Khan, J P Slavin
Journal: Gut (2009)

We read the article by Morris et al ( Gut : Epub ahead of print doi:10.1136/gut.2007.137877) with interest; we feel however that a number of important points need to be clarified by the authors.

There is nearly a 25% reduction in the abdominoperineal resection (APER) rate during the 6-year study period; downsizing and downstaging of the tumour following neoadjuvant chemoradiotherapy which technically enables an anterior resection (AR) to be performed may in part explain this reduction.

Further, although the median rectal cancer surgery workload was only 2.5 per year in England during the study period, it is likely that with reorganisation of colorectal cancer services that this has increased.

The type of surgical resection for rectal cancer is based on tumour characteristics, …
A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Authors: U Tirelli, V Zagonel, D Errante, D Serraino, R Talamini, M De Cicco, A Carbone, S Monfardini
Journal: Journal of Clinical Oncology (1992)

PURPOSE A prospective trial with a new combination of etoposide, mitoxantrone, and prednimustine (VMP), specifically devised for elderly patients with non-Hodgkin's lymphoma (NHL), was undertaken. PATIENTS AND METHODS Between January 1987 and April 1990, 52 consecutive unselected patients older than 70 years (median age, 75.6 years) with stage I to IV intermediate- and high-grade NHL, or with stage III to IV low-grade malignancy with symptomatic disease received etoposide and prednimustine 80 mg/m2 orally for 5 days and mitoxantrone 8 to 10 mg/m2 day 1 intravenously (IV), every 21 days. Fourteen patients were previously treated. RESULTS Among the 48 assessable patients, the objective response rate was 81%; 46% of the patients achieved a complete response (CR). The overall toxicity seemed to be acceptable, with 15 (7%) episodes of grade 4 leukopenia and 41 (18%) episodes of grade 3, over a total of 226 administered cycles. The median survival was 12 months. The patients who obtained CR have a longer survival than those who did not (34 v 8 months; P less than .001). Fifty-eight percent of patients achieving CR were free from relapse at 24 months; up to 36 months from the start of therapy, 25% were free from relapse. As far as patients affected by diffuse histiocytic lymphoma, 66% of previously untreated patients obtained a CR, and 55% of them were still disease-free at 24 months from the start of therapy. CONCLUSION We conclude that VMP is effective, well tolerated, and feasible on an outpatient basis in an unselected, elderly population affected by unfavorable NHL.
Inheritance of Factors Affecting the Ability of Bone Marrow of (C57BL × 101)F&lt;sub&gt;2&lt;/sub&gt; Mice to Establish Permanent Grafts in Irradiated F&lt;sub&gt;1&lt;/sub&gt; Mice
Authors: Raymond A. Popp
Journal: JNCI Journal of the National Cancer Institute (1964)

Marrow from (C57BL × 101)F2 mice was injected intravenously into irradiated (C57BL × 101)F1 recipients. Each donor was classified for H-2 serotype, hemoglobin, coat color, and sex. Of the F2 mice, 13.3 percent had marrow cells similar to those of the C57BL parent, judged by a reduced ability of the marrow to establish long-term grafts in irradiated F1 mice. Thus, the factors associated with the regression of C57BL marrow grafts in F1 recipients appear inheritable, but the number of factors and their biological nature are not known. The factors are not sex-linked nor linked with H-2, Hb, or A. The survivals of F1 recipients of F2 marrow of phenotypes H-2 b/k, H-2 b/b, and H-2 k/k were 94.8, 83.5, and 81.0 percent, respectively, which shows that differences in the survival of the recipients are correlated with H-2 incompatibility. However, differences in the survival of F1 recipients of C57BL compared with 101 marrow (31.4 and 70.4%, respectively) cannot be ascribed solely to differences in the immunological competence of the H-2 b/b and H-2 k/k of C57BL and 101 marrow, respectively, since the survival of F1 recipients of F2 marrow of H-2 b/b and H-2 k/k genotypes is similar.
The Causes of Dysphagia in Carcinoma of the Lung
Authors: D R Camidge
Journal: Journal of the Royal Society of Medicine (2001)

Dysphagia occurs in only a small percentage of patients with lung cancer, but the frequency of this cancer means that large numbers are affected. Non-quantitative analysis of a large Scottish series of lung cancer cases indicates the following eight broad categories of dysphagia according to underlying mechanisms: mediastinal disease; cervical lymphadenopathy; brainstem lesions; gastrointestinal tract metastases; associated systemic disorders; second primaries; oropharyngeal and oesophageal infections; and radiation-induced oesophageal toxicity.
Increased Clearance of Antipyrine and d-Propranolol after Phenobarbital Treatment in the Monkey
Authors: Robert A. Branch, David G. Shand, Grant R. Wilkinson, Alan S. Nies
Journal: Journal of Clinical Investigation (1974)

The effects of phenobarbital treatment for 12 days on the regional distribution of blood flow and on the disposition of two model drugs, antipyrine and d-propranolol, have been determined in six unanesthetized rhesus monkeys. Phenobarbital significantly increased total hepatic blood flow from 179+/-15 to 239+/-27 ml/min. Liver weight was increased to a similar degree (34%) in phenobarbital-treated animals as compared to control monkeys. The clearance of both antipyrine and d-propranolol was increased and the half-life decreased significantly by phenobarbital. Analysis of the data by a perfusion-limited pharmacokinetic model showed that the changes in antipyrine clearance were due almost entirely to enzyme induction. On the other hand, with d-propranolol, the increase in liver blood flow contributed as much to the enhanced clearance as did the stimulation of drug metabolism. The mechanism by which phenobarbital produces the frequently observed increase in drug clearance, therefore, depends upon the initial clearance value of the drug. For low clearance drugs like antipyrine, clearance changes occur largely as a result of enzyme induction. With higher clearance drugs, the effects of increased hepatic blood flow become progressively more important the greater the initial clearance value.
Abstract 4984: Trends in 10-year Risk of Incident Cardiovascular Disease in the United States, 1972–2004
Authors: Francisco Lopez-Jimenez, John A Batsis, Henry H Ting, Virend K Somers
Journal: Circulation (2008)

Background : The significant bidirectional changes in cardiovascular(CV) risk factor prevalence make the net trend in incident CV risk unknown. We assessed the trends in the net 10-year risk for incident CV disease using the Framingham risk model and data from the National Health and Nutrition Examination Surveys(NHANES). Methods : We used data from NHANES II (1976–1980), NHANES III (1988–1994), and NHANES 1999–2004, including major CV risk factors, all collected in a standardized manner. People with a history of CV disease, pregnant women, people with missing data and those outside the Framingham age range were excluded. The Framingham risk function estimated the 10-year risk for CV disease. The slope of change or rate of change per year between NHANES II/III, and between NHANES III/1999–2004 were determined. The slope difference was calculated and compared to zero. Results : The mean age-adjusted 10-year CV risk decreased from 10 to 7.9% between NHANES II and III, with a significant slope (p&lt;0.001). However, the mean age-adjusted risk decreased to a lesser extent between NHANES III and NHANES 1999–2004 from 7.9 to 7.4% (p&lt;0.001). The slopes were different (p&lt;0.001). In women, CV risk did not change between NHANES III and 1999–2004, 7.9 to 7.5%, (p=0.40). Predicted 10-year risk by age group (Figure ) shows that the decrease in CV risk was lower in the second period compared to the first one in all age groups, except in the elderly. Conclusion : The estimated net risk for CV disease in the US population decreased from 1976–1980 to 1988–1994 but minimally changed from 1988–1994 to 1999–2004, particularly in women. The increased prevalence of obesity may have offset the gain in CV risk reduction. Predicted 10-year Framingham Risk by Age Group
Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II Study
Authors: Vittorio Gebbia, Francesco Giuliani, Evaristo Maiello, Giuseppe Colucci, Francesco Verderame, Nicoló Borsellino, Gaetano Mauceri, Michele Caruso, Maria Lina Tirrito, Matteo Valdesi
Journal: Journal of Clinical Oncology (2001)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.20.4089 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11600613 Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II Study Vittorio GebbiaxVittorio GebbiaSearch for articles by this author , Francesco GiulianixFrancesco GiulianiSearch for articles by this author , Evaristo MaielloxEvaristo MaielloSearch for articles by this author , Giuseppe ColuccixGiuseppe ColucciSearch for articles by this author , Francesco VerderamexFrancesco VerderameSearch for articles by this author , Nicoló BorsellinoxNicoló BorsellinoSearch for articles by this author , Gaetano MaucerixGaetano MauceriSearch for articles by this author , Michele CarusoxMichele CarusoSearch for articles by this author , Maria Lina TirritoxMaria Lina TirritoSearch for articles by this author , Matteo ValdesixMatteo ValdesiSearch for articles by this author Show More University of Palermo, La Maddalena Clinic for Cancer, Palermo, ItalyNational Institute of Oncology, Bari, ItalyOspedali Riuniti, Sciacca, ItalyLa Maddalena Clinic for Cancer, Palermo, ItalyCentro Catanese de Oncologia, Catania, ItalyCasa di Cura Torina, Palermo, ItalyOspedale Buccheri La Ferla, Palermo, Italy https://doi.org/10.1200/JCO.2001.19.20.4089 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
A comprehensive review of current treatments for granulomatous cheilitis
Authors: T. Banks, S. Gada
Journal: British Journal of Dermatology (2011)

Journal Article A comprehensive review of current treatments for granulomatous cheilitis Get access T. Banks, MD, T. Banks, MD Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889‐5600, U.S.A Taylor Banks. E‐mail: taylor.banks@med.navy.mil Search for other works by this author on: Oxford Academic Google Scholar S. Gada, MD S. Gada, MD Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889‐5600, U.S.A Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 166, Issue 5, 1 May 2012, Pages 934–937, https://doi.org/10.1111/j.1365-2133.2011.10794.x Published: 01 May 2012 Article history Accepted: 07 December 2011 Published: 01 May 2012
Smoking and effect of chemotherapy in small cell lung cancer
Authors: B Bergman, S Sorenson
Journal: European Respiratory Journal (1988)

The relationship between smoking habits and outcome of treatment was studied in 154 patients with small cell lung cancer (SCLC) who received combination chemotherapy. Thirty-two patients had stopped smoking at least 6 months before the initiation of treatment or had never smoked (NS), 51 patients stopped smoking less than 6 months prior to the start of treatment (SS) and 71 patients continued to smoke during the treatment period (CS). Life table analysis of overall survival showed no significant heterogeneity among the groups (p greater than 0.7). Chi-square test for trend in survival yielded 0.23 (p greater than 0.6) with the longest survival in SS and CS patients, and the shortest survival in NS patients. Corresponding analysis of time to progression showed similar results, with a non-significant heterogeneity (p greater than 0.5) and trend (p greater than 0.4) among the three groups, with the CS patients doing best. In the whole series the disease-free two-year survival rate was higher in the CS patients than in the SS and NS patients (p = 0.04). The results do not imply that continued smoking during chemotherapy in SCLC has unfavourable effects on the outcome of treatment.
Estrogen Receptor and Alpha-Fetoprotein in Human Breast Cancer: Brief Communication 2
Authors: K. Nakao, H. Ochi, M. Kawashima, S. Tomino, H. Sugano, K. Matsumoto
Journal: JNCI Journal of the National Cancer Institute (1978)

Concentrations of estrogen receptor (ER) and alpha-fetoprotein were determined by dextran-coated charcoal assay and analyzed with Scatchard plots and radioimmunoassay, respectively, in cytosols of 72 human breast cancers. The values for ER ranged from 0 to 340 fmoles/mg cytosol protein. The concentrations of alpha-fetoprotein, which were low in all tumor cytosols examined, ranged from less than 0.1 to 1.1 ng/mg cytosol protein. No positive relationship was found between ER and alpha-fetoprotein concentrations. These results show that ER, but not alpha-fetoprotein, usually accounts for most of the high estrogen-binding capacity in cytosols of human breast cancers.